The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study

Simple item page
dc.contributor.buuauthorSivrioğlu, Enver
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.buuauthorSipahioğlu, Deniz
dc.contributor.buuauthorGürsoy, Babar
dc.contributor.buuauthorSarandol, Emre
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.contributor.researcheridABE-1716-2020tr_TR
dc.contributor.scopusid14062563200tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.contributor.scopusid19640368300tr_TR
dc.contributor.scopusid56764165800tr_TR
dc.contributor.scopusid55943324800tr_TR
dc.date.accessioned2022-08-17T09:42:50Z
dc.date.available2022-08-17T09:42:50Z
dc.date.issued2007-01-01
dc.description.abstractClassical antipsychotics like haloperidol are suggested to increase oxidative stress and oxidative cell injury in the brain. Pro-oxidant effect of haloperidol may influence the course and treatment outcomes of schizophrenia. Dietary supplementation of either antioxidants or ω-3 fatty acids was found to improve symptoms of schizophrenia. Thus we decided to assess the impact of combining ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol. Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of ω-3 fatty acids (180 mg EPA + 120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day. Patients were assessed with Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Simpson Angus Scale (SAS) and Barnes Akathisia Rating Scale (BARS) over a 4 month period. Gluthatione peroxidase, superoxide dismutase, malondialdehyde, vitamin E and C levels were also evaluated at baseline and at the end of study. BPRS, SANS, SAS and BARS scores obtained at follow-up visits were significantly lower compared to baseline. Superoxide dismutase level was significantly lower at the end of study. No significant differences were detected in other laboratory parameters. Our results support the beneficial effect of the supplementation on positive and negative symptoms of schizophrenia as well as the severity of side effects induced by haloperidol. The effect of supplementation on akathisia is especially noteworthy and it has not been investigated in previous studies.en_US
dc.identifier.citationSivrioğlu, E. Y. vd. (2007). "The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study". Progress In Neuro-Psychopharmacology & Biologıcal Psychiatry, 31(7), 1493-1499.en_US
dc.identifier.endpage1499tr_TR
dc.identifier.issn02785846
dc.identifier.issue7tr_TR
dc.identifier.pubmed17688987tr_TR
dc.identifier.scopus2-s2.0-34548129985tr_TR
dc.identifier.startpage1493tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2007.07.004
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0278584607002291
dc.identifier.urihttp://hdl.handle.net/11452/28226
dc.identifier.volume31tr_TR
dc.identifier.wos000249679100022tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherPergamon Elsevier Scienceen_US
dc.relation.journalProgress In Neuro-Psychopharmacology & Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEthyl-eicosapentaenoic aciden_US
dc.subjectω-3 fatty acidsen_US
dc.subjectAkathisiaen_US
dc.subjectAntioxidantsen_US
dc.subjectSchizophreniaen_US
dc.subjectVitamin Cen_US
dc.subjectVitamin Een_US
dc.subjectFree-radical pathologyen_US
dc.subjectOxidative stressen_US
dc.subjectAntioxidant defenseen_US
dc.subjectRating-scaleen_US
dc.subjectCombinationen_US
dc.subjectApoptosisen_US
dc.subjectSymptomsen_US
dc.subjectDiseaseen_US
dc.subjectEnzymesen_US
dc.subject.emtreeSuperoxide dismutaseen_US
dc.subject.emtreeAlpha tocopherolen_US
dc.subject.emtreeAscorbic aciden_US
dc.subject.emtreeBiperidenen_US
dc.subject.emtreeGlutathione peroxidaseen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeIcosapentaenoic aciden_US
dc.subject.emtreeMalonaldehydeen_US
dc.subject.emtreeOmega 3 fatty aciden_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAkathisiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBrief psychiatric rating scaleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeOpen studyen_US
dc.subject.emtreePilot studyen_US
dc.subject.emtreeSchizophreniaen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeVitamin supplementationen_US
dc.subject.meshAkathisia, drug-induceden_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshFatty acids, omega-3en_US
dc.subject.meshAntioxidantsen_US
dc.subject.meshAntipsychotic agentsen_US
dc.subject.meshAscorbic aciden_US
dc.subject.meshErythrocytesen_US
dc.subject.meshFemaleen_US
dc.subject.meshSchizophrenic psychologyen_US
dc.subject.meshHaloperidolen_US
dc.subject.meshHumansen_US
dc.subject.meshLipid peroxidationen_US
dc.subject.meshMaleen_US
dc.subject.meshMalondialdehydeen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPilot projectsen_US
dc.subject.meshSchizophreniaen_US
dc.subject.meshSuperoxide dismutaseen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshVitamin Een_US
dc.subject.scopusSchizophrenia; Acetylcysteine; Bipolar Disorderen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleThe impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot studyen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus